Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

ETS1 induces transforming growth factor β signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.

Rodgers JJ, McClure R, Epis MR, Cohen RJ, Leedman PJ, Harvey JM; Australian Prostate Cancer BioResource, Thomas MA, Bentel JM.

J Cell Biochem. 2018 Aug 30. doi: 10.1002/jcb.27446. [Epub ahead of print]

PMID:
30161276
2.

A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer.

Matin F, Jeet V, Moya L, Selth LA, Chambers S; Australian Prostate Cancer BioResource, Clements JA, Batra J.

Sci Rep. 2018 Apr 27;8(1):6653. doi: 10.1038/s41598-018-24424-w.

3.

A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness.

Lai J, Moya L, An J, Hoffman A, Srinivasan S, Panchadsaram J, Walpole C, Perry-Keene JL, Chambers S; Australian Prostate Cancer BioResource, Lehman ML, Nelson CC, Clements JA, Batra J.

Sci Rep. 2017 Dec 4;7(1):16862. doi: 10.1038/s41598-017-16700-y.

4.

Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.

Kryza T, Silva LM, Bock N, Fuhrman-Luck RA, Stephens CR, Gao J, Samaratunga H; Australian Prostate Cancer BioResource, Lawrence MG, Hooper JD, Dong Y, Risbridger GP, Clements JA.

Mol Oncol. 2017 Oct;11(10):1307-1329. doi: 10.1002/1878-0261.12075. Epub 2017 Aug 10.

5.

Characterisation of microbial communities within aggressive prostate cancer tissues.

Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J; Australian Prostate Cancer BioResource, Giles GG, Southey MC.

Infect Agent Cancer. 2017 Jan 13;12:4. doi: 10.1186/s13027-016-0112-7. eCollection 2017.

6.

A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.

Armstrong HK, Koay YC, Irani S, Das R, Nassar ZD; Australian Prostate Cancer BioResource, Selth LA, Centenera MM, McAlpine SR, Butler LM.

Prostate. 2016 Dec;76(16):1546-1559. doi: 10.1002/pros.23239. Epub 2016 Aug 16.

PMID:
27526951
7.

High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.

Xie J, Mølck C, Paquet-Fifield S, Butler L; Australian Prostate Cancer Bioresource, Sloan E, Ventura S, Hollande F.

Oncotarget. 2016 Jul 12;7(28):44492-44504. doi: 10.18632/oncotarget.9876.

8.

Erratum to: Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2016 Jun 3;17(1):424. No abstract available.

9.

Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2015 Dec 1;16:1021. doi: 10.1186/s12864-015-2235-4. Erratum in: BMC Genomics. 2016;17:424.

10.

Genome-wide association study of prostate cancer-specific survival.

Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubiński J, Kluźniak W, Cannon-Albright L, Brenner H, Herrmann V, Holleczek B, Park JY, Sellers TA, Lim HY, Slavov C, Kaneva RP, Mitev VI, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A; PRACTICAL consortium, Batra J, Clements JA; Australian Prostate Cancer BioResource, Albanes D, Andriole GL, Berndt SI, Chanock S, Gapstur SM, Giovannucci EL, Hunter DJ, Kraft P, Le Marchand L, Ma J, Mondul AM, Penney KL, Stampfer MJ, Stevens VL, Weinstein SJ, Trichopoulou A, Bueno-de-Mesquita BH, Tjønneland A, Cox DG; BPC3 consortium, Maehle L, Schleutker J, Lindström S, Wiklund F.

Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1796-800. doi: 10.1158/1055-9965.EPI-15-0543. Epub 2015 Aug 25.

11.

Prediction of individual genetic risk to prostate cancer using a polygenic score.

Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai ZS, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubiński J, Kluźniak W, Cannon-Albright L, Brenner H, Butterbach K, Stegmaier C, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA; Australian Prostate Cancer BioResource, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A; Practical Consortium, Gronberg H, Wiklund F.

Prostate. 2015 Sep;75(13):1467-74. doi: 10.1002/pros.23037. Epub 2015 Jul 14. Erratum in: Prostate. 2015 Dec;75(16):1972. Lim, Hui-Yi [corrected to Lin, Hui-Yi].

PMID:
26177737
12.

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; Australian Prostate Cancer BioResource; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.

13.

A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.

Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR; PRACTICAL Consortium; Australian Prostate Cancer BioResource, Spurdle AB, Clements JA, Park JY, Batra J.

Cancer Discov. 2015 Apr;5(4):368-79. doi: 10.1158/2159-8290.CD-14-1057. Epub 2015 Feb 17.

14.

PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.

Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Lê Cao KA, Winterford C, Coward JI, Ling MT; Australian Prostate Cancer BioResource, Craik DJ, Parton RG, Russell PJ, Hill MM.

Oncogene. 2014 Jul 3;33(27):3561-70. doi: 10.1038/onc.2013.315. Epub 2013 Aug 12.

PMID:
23934189
15.

A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors.

Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM; Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP.

Sci Transl Med. 2013 May 29;5(187):187ra71. doi: 10.1126/scitranslmed.3005688.

16.

A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer.

Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen JS, Norden S, Frydenberg M, Grummet JP, Pook DW; Australian Prostate Cancer BioResource, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, Hutmacher DW, Risbridger GP.

Biomaterials. 2013 Jul;34(20):4777-85. doi: 10.1016/j.biomaterials.2013.03.005. Epub 2013 Apr 2.

PMID:
23562048
17.

A preclinical xenograft model of prostate cancer using human tumors.

Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M; Australian Prostate Cancer BioResource, Papargiris MM, Niranjan B, Richards MG, Wang H, Collins AT, Maitland NJ, Risbridger GP.

Nat Protoc. 2013 May;8(5):836-48. doi: 10.1038/nprot.2013.043. Epub 2013 Apr 4.

PMID:
23558784
18.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF.

Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi: 10.1038/ng.2560.

19.

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; Australian Prostate Cancer Bioresource; PRACTICAL Consortium, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA.

Hum Mol Genet. 2013 Jan 15;22(2):408-15. doi: 10.1093/hmg/dds425. Epub 2012 Oct 12.

20.

Genetic association of the KLK4 locus with risk of prostate cancer.

Lose F, Srinivasan S, O'Mara T, Marquart L, Chambers S, Gardiner RA, Aitken JF; Australian Prostate Cancer BioResource, Spurdle AB, Batra J, Clements JA.

PLoS One. 2012;7(9):e44520. Epub 2012 Sep 6.

Supplemental Content

Loading ...
Support Center